These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12871560)

  • 1. Multi-therapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease.
    Boyer-Neumann C; Dreyfus M; Wolf M; Veyradier A; Meyer D
    J Thromb Haemost; 2003 Jan; 1(1):190-2. PubMed ID: 12871560
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Using recombinant activated coagulation factor VII (NovoSeven) in obstetrics].
    Pekhlivanov B; Milchev N; Abrashev B
    Akush Ginekol (Sofiia); 2003; 42(6):7-9. PubMed ID: 15067806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous infusion of recombinant factor VIIa (NovoSeven) in the treatment of a patient with type III von Willebrand's disease and alloantibodies against von Willebrand factor.
    Grossmann RE; Geisen U; Schwender S; Keller F
    Thromb Haemost; 2000 Apr; 83(4):633-4. PubMed ID: 10780333
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor.
    Ciavarella N; Schiavoni M; Valenzano E; Mangini F; Inchingolo F
    Haemostasis; 1996; 26 Suppl 1():150-4. PubMed ID: 8904191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How I treat patients with von Willebrand disease.
    Mannucci PM
    Blood; 2001 Apr; 97(7):1915-9. PubMed ID: 11264151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of von Willebrand disease type 3 during pregnancy - 2 cases reports.
    Inocêncio G; Braga A; Azevedo S; Buchner G
    Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2857-9. PubMed ID: 24254552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New approach of the treatment of von Willebrand's disease during pregnancy.
    Gojnic M; Fazlagic A; Likic I; Stefanovic A; Vidakovic S; Pervulov M; Petkovic S; Mostic T; Miljic P; Bogdanovic A
    Arch Gynecol Obstet; 2005 Nov; 273(1):35-8. PubMed ID: 16172853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use and Future Investigations of Recombinant and Plasma-Derived Coagulation and Anticoagulant Products in the Neonate.
    Punzalan RC; Gottschall JL
    Transfus Med Rev; 2016 Oct; 30(4):189-96. PubMed ID: 27576087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of recombinant factor VIIa in inherited and acquired von Willebrand disease.
    Sucker C; Scharf RE; Zotz RB
    Clin Appl Thromb Hemost; 2009 Feb; 15(1):27-31. PubMed ID: 18263636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of delivery with FVIII/VWF concentrates in a pregnant woman with type 3 von Willebrand disease and alloantibodies.
    Martín-Salces M; Jiménez-Yuste V; Álvarez-Román MT; Rivas-Pollmar I; Rodríguez de la Rúa A
    Thromb Haemost; 2012 Oct; 108(4):796-8. PubMed ID: 22836221
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment for patients with type 3 von Willebrand disease and alloantibodies: a case report.
    Franchini M; Gandini G; Giuffrida A; De Gironcoli M; Federici AB
    Haemophilia; 2008 May; 14(3):645-6. PubMed ID: 18312363
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful use of recombinant factor VIIa for massive bleeding after caesarean section due to HELLP syndrome.
    Zupancić Salek S; Sokolić V; Visković T; Sanjug J; Simić M; Kastelan M
    Acta Haematol; 2002; 108(3):162-3. PubMed ID: 12373090
    [No Abstract]   [Full Text] [Related]  

  • 14. Pregnancy and delivery in women with von Willebrand's disease and different von Willebrand factor mutations.
    Castaman G; Tosetto A; Rodeghiero F
    Haematologica; 2010 Jun; 95(6):963-9. PubMed ID: 19951969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anesthetic management of cesarean section in a patient with type II von Willebrand disease].
    Ito H; Satoh M; Seo N
    Masui; 2008 Feb; 57(2):203-5. PubMed ID: 18277572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of patients with Type 2B von Willebrand's disease during delivery and puerperium].
    Güth U; Tsakiris DA; Reber A; Holzgreve W; Hösli I
    Z Geburtshilfe Neonatol; 2002; 206(4):151-5. PubMed ID: 12198592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Von Willebrand disease: a nursing perspective.
    Kleinert D; Orto C; Gioia K; Hannan M
    J Obstet Gynecol Neonatal Nurs; 1997; 26(3):271-6. PubMed ID: 9170590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab for the treatment of high titre inhibitors in mild haemophilia A.
    Dolničar MB; Rajić V; Kitanovski L; Debeljak M
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s345-7. PubMed ID: 23522890
    [No Abstract]   [Full Text] [Related]  

  • 19. Pregnancy in women with type 1 von Willebrand disease caused by heterozygosity for von Willebrand factor mutation C1130F.
    Castaman G; Eikenboom JC; Contri A; Rodeghiero F
    Thromb Haemost; 2000 Aug; 84(2):351-2. PubMed ID: 10959713
    [No Abstract]   [Full Text] [Related]  

  • 20. von Willebrand disease, pregnancy and neuraxial anesthesia: a multi-disciplinary approach for successful regional anesthesia.
    Kailash F; Wilkerson D
    J Ark Med Soc; 2009 May; 105(11):259-60, 262. PubMed ID: 19475813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.